In previous studies of patients with thyroid cancer treated with Lenvatinib, an oral TKI that targets VEGFR and PDGFR, NLR was found to be a prognostic marker for differentiated thyroid cancer [16] and anaplastic thyroid cancer [17]. This evidence concerns the gene PDGFRB and thyroid gland undifferentiated (anaplastic) carcinoma.